Format

Send to

Choose Destination
Int J Mol Sci. 2016 Aug 12;17(8). pii: E1320. doi: 10.3390/ijms17081320.

G Protein-Coupled Receptors in Cancer.

Author information

1
Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel. Rachelbar@ekmd.huji.ac.il.
2
Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel. Myriamm@hadassah.org.il.
3
Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel. kancharlarn@gmail.com.
4
Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel. jeetendr.nag@mail.huji.ac.il.
5
Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel. Danyaag@gmail.com.
6
Department of Obstetrics and Gynecology, Shaare-Zedek Medical Center, Jerusalem 91031, Israel. sorina@szmc.org.il.
7
Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel. Beatrice@hadassah.org.il.

Abstract

Despite the fact that G protein-coupled receptors (GPCRs) are the largest signal-conveying receptor family and mediate many physiological processes, their role in tumor biology is underappreciated. Numerous lines of evidence now associate GPCRs and their downstream signaling targets in cancer growth and development. Indeed, GPCRs control many features of tumorigenesis, including immune cell-mediated functions, proliferation, invasion and survival at the secondary site. Technological advances have further substantiated GPCR modifications in human tumors. Among these are point mutations, gene overexpression, GPCR silencing by promoter methylation and the number of gene copies. At this point, it is imperative to elucidate specific signaling pathways of "cancer driver" GPCRs. Emerging data on GPCR biology point to functional selectivity and "biased agonism"; hence, there is a diminishing enthusiasm for the concept of "one drug per GPCR target" and increasing interest in the identification of several drug options. Therefore, determining the appropriate context-dependent conformation of a functional GPCR as well as the contribution of GPCR alterations to cancer development remain significant challenges for the discovery of dominant cancer genes and the development of targeted therapeutics.

KEYWORDS:

CXCR4; G protein-coupled receptors (GPCRs); Hippo/YAP; LPA(1-6); PH-domain; Wnt/β-catenin; cancer; oncogenes; protease; protease-activated receptor; protease-activated receptors (PARs)

PMID:
27529230
PMCID:
PMC5000717
DOI:
10.3390/ijms17081320
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center